Recon: FDA again uncovers quality problems at Eli Lilly’s New Jersey site; Viatris considering $3B sale of its consumer drug division
ReconJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy